3 Complex Generics and Oncology Company, Active Ingredients Specialist and Contract Formulations Maker Stocks With a Strong Future Roadmap: Natco Pharma, Neuland Laboratories and Innova Captab
- October 28, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Natco Pharma, Neuland Laboratories and Innova Captab: ROE of 12.9% to 19.4% and FY22 to FY26 revenue CAGR of 19.5% to 21.1%. Prices as of 27 Oct 2026.
Quick Answer
The three oncology, ingredient and contract pharma to watch are Natco Pharma, Neuland Laboratories and Innova Captab. Their return on equity ranges from 12.9% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 19.5% to 21.1%. Neuland Laboratories leads on both return on equity at 19.4% and revenue growth at 21.1% a year. Prices are based on the 27 October 2026 close, and this article is educational, not investment advice.
Oncology, ingredient and contract pharma offer a focused view of a sector where demand keeps widening. Natco Pharma, Neuland Laboratories and Innova Captab cover a complex generics and oncology company, an active ingredients specialist and a contract formulations maker.
This list covers three oncology, ingredient and contract pharma with complete current figures: Natco Pharma, Neuland Laboratories and Innova Captab. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Oncology, Ingredient and Contract Pharma?
Oncology, ingredient and contract pharma are listed pharmaceutical companies that focus on complex generics and oncology medicines, make active ingredients and custom synthesis products and manufacture formulations for other drug makers. Their earnings depend on launches, approvals and customer orders.
Oncology, Ingredient and Contract Pharma at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Natco Pharma | 794.55 | 15,708 | 13.7 | 36.0 | 15.4 | 0.08 |
| Neuland Laboratories | 19,315 | 24,665 | 49.5 | 36.0 | 19.4 | 0.16 |
| Innova Captab | 1,062.6 | 5,736 | 37.2 | 36.0 | 12.9 | 0.32 |
On valuation, Natco Pharma trades at a P/E below the industry P/E, while Neuland Laboratories and Innova Captab trade above it, which reflects the growth the market already expects. Readers comparing oncology, ingredient and contract pharma should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Oncology, Ingredient and Contract Pharma Have a Strong Roadmap in India?
Oncology, ingredient and contract pharma have a strong roadmap in India because demand for complex generics, outsourcing of drug manufacturing and rising healthcare spending keep widening the market for Indian pharmaceutical firms.
- Complex generics. Difficult products carry steadier demand.
- Custom synthesis. Customers need specialised ingredients.
- Contract output. Drug makers outsource formulation work.
Why Natco Pharma Features Among These Oncology, Ingredient and Contract Pharma
Among the oncology, ingredient and contract pharma on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.
The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0.
Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.
Roadmap: The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.
What to watch: Check the timing of key product launches in the US and the contribution from new drug approvals.
Why Neuland Laboratories Features Among These Oncology, Ingredient and Contract Pharma
Among the complex generics, APIs and contract formulations shares on this list, Neuland Laboratories, based in Hyderabad, makes active pharmaceutical ingredients for generic drugs and runs a custom manufacturing business that supplies innovator companies.
Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%.
The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0.
Roadmap: The company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.
What to watch: Custom manufacturing revenue can move between quarters, so review the full-year trend.
Why Innova Captab Features Among These Oncology, Ingredient and Contract Pharma
Among the three companies on this list, Innova Captab is a Himachal Pradesh-based pharmaceutical company that makes formulations for other pharma companies, manufactures its own branded generics and supplies active ingredients.
In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%.
Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0.
Roadmap: The company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.
What to watch: Watch the growth in the branded business and the utilisation of expanded capacity.
Natco Pharma vs Neuland Laboratories vs Innova Captab on Key Financials
The table below sets the three oncology, ingredient and contract pharma side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Natco Pharma | 2,044 | 4,376 | 21.0% | 1,372 | 31.4% |
| Neuland Laboratories | 953 | 2,053 | 21.1% | 364 | 17.7% |
| Innova Captab | 803 | 1,637 | 19.5% | 141 | 8.6% |
Neuland Laboratories posts the highest return on equity in this group at 19.4%. Natco Pharma has the largest FY26 revenue at Rs 4,376 crore, and Neuland Laboratories shows the fastest revenue growth with a 21.1% compound annual rate.
Key Risks to Check Before Investing in Oncology, Ingredient and Contract Pharma
Every theme carries risks that deserve a check before any decision. For these oncology, ingredient and contract pharma, the main points are:
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Pricing pressure. Generic prices can change by market.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter oncology, ingredient and contract pharma by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Oncology, Ingredient and Contract Pharma
Oncology, ingredient and contract pharma reward patient research into demand, execution and financial strength. Natco Pharma, Neuland Laboratories and Innova Captab each have a clear plan to expand. Based on the 27 October 2026 close, Natco Pharma trades at Rs 794.55, Neuland Laboratories at Rs 19,315 and Innova Captab at Rs 1,062.6.
Download the Univest iOS App or Univest Android App to track oncology, ingredient and contract pharma, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are oncology, ingredient and contract pharma?
Ans. Oncology, ingredient and contract pharma are listed pharmaceutical companies that focus on complex generics and oncology medicines, make active ingredients and custom synthesis products and manufacture formulations for other drug makers. Their earnings depend on launches, approvals and customer orders. This list looks at three of them, Natco Pharma, Neuland Laboratories and Innova Captab, using reported FY22 to FY26 financials and the 27 October 2026 closing prices.
Which oncology, ingredient and contract pharma are covered in this list?
Ans. This list covers Natco Pharma, Neuland Laboratories and Innova Captab. Based on the 27 October 2026 close, Natco Pharma traded at Rs 794.55, Neuland Laboratories at Rs 19,315 and Innova Captab at Rs 1,062.6. Their return on equity ranges from 12.9% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 19.5% to 21.1%.
Why do oncology, ingredient and contract pharma have a strong future roadmap in India?
Ans. Oncology, ingredient and contract pharma have a strong roadmap in India because demand for complex generics, outsourcing of drug manufacturing and rising healthcare spending keep widening the market for Indian pharmaceutical firms. The main drivers are as follows. Complex generics. Difficult products carry steadier demand. Custom synthesis. Customers need specialised ingredients. Contract output. Drug makers outsource formulation work. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Natco Pharma performed financially?
Ans. Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.
How has Neuland Laboratories performed financially?
Ans. Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0. Looking ahead, the company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.
How has Innova Captab performed financially?
Ans. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.
What risks should investors check before buying oncology, ingredient and contract pharma?
Ans. Investors should check a few risks before buying oncology, ingredient and contract pharma. Regulatory approvals. Plant inspections and approvals can affect supplies. Pricing pressure. Generic prices can change by market. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of oncology, ingredient and contract pharma investment advice?
Ans. No. This article is educational and uses publicly available data as of the 27 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.